References
- BreivikHCollettBVentafriddaVCohenRGallacherDSurvey of chronic pain in Europe: prevalence, impact on daily life, and treatmentEur J Pain20061028733316095934
- RustoenTWahlAKHanestadBRLerdalAPaulSMiaskowskiCPrevalence and characteristics of chronic pain in the general Norwegian populationEur J Pain2004855556515531224
- SjøgrenPEkholmOPeuckmannVGrønbaekMEpidemiology of chronic pain in Denmark: an updateEur J Pain20091328729218547844
- AnnemansLPharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent painClin Drug Investig2011317386
- AnderssonGBEpidemiological features of chronic low-back painLancet199935458158510470716
- MapelDWShainlineMPaezKGunterMHospital, pharmacy, and outpatient costs for osteoarthritis and chronic back painJ Rheumatol20043157358314994407
- HartLGDeyoRACherkinDCPhysician office visits for low back pain: frequency, clinical evaluation, and treatment patterns from a US national surveySpine19952011197709270
- EkmanMJohnellOLidgrenLThe economic cost of low back pain in Sweden in 2001Acta Orthop20057627528416097556
- StewartWFRicciJACheeEMorgansteinDLiptonRLost productive time and cost due to common pain conditions in the US workforceJAMA20032902443245414612481
- KuritzkyLBarnettADoanHThe 10-minute examination for low back painJ Musculoskelet Med200219497505
- TurkDCOkifujiAPain terms and taxonomies of painLoeserJDButlerSHChapmanCRTurkDCBonica’s Management of Pain3rd edBaltimore, MarylandLippincott Williams & Wilkins20011725
- RaffaRBPergolizziJVTallaridaRJThe determination and application of fixed-dose analgesic combinations for treating multimodal painJ Pain20101170170920338825
- LivengoodJMPsychologic and psychosocial factors contributing to chronic painCurr Rev Pain1999319
- LameIEPetersMLVlaeyenJWKleefMPatijinJQuality of life in chronic pain is more associated with beliefs about pain, than with pain intensityEur J Pain20059152415629870
- Van TulderMKoesBBombardierCLow back painBest Pract Res Clin Rheumatol20021676177512473272
- PaiSSundaramLJLow back pain: an economic assessment in the United StatesOrthop Clin North Am2004351515062712
- Backpain EuropeEuropean Guidelines For the Management of Chronic Non-Specific Low Back Pain (Amended Version) http://www.backpaineurope.org/web/files/WG2_Guidelines.pdf. Accessed September 28, 2009.
- PortenoyRKKannerRMDefinition and assessment of painPortenoyRKKannerRMPain Management Theory and PracticePhiladelphia, PAFA Davis Co1996318
- GalerBSDworkinRHA Clinical Guide to Neuropathic PainMinneapolis, MinnesotaThe McGraw-Hill Companies Inc2000
- FreynhagenRBaronRGockelUTölleTRpainDETECT: a new screening questionnaire to identify neuropathic components in patients with back painCurr Med Res Opin2006221911192017022849
- HardenNCohenMUnmet needs in the management of neuropathic painJ Pain Symptom Manage200325Suppl 5S12S1712694988
- GilronIMaxMBCombination pharmacotherapy for neuropathic pain: current evidence and future directionsExpert Rev Neurotherapeutics20055823830
- MartellBAO’ConnorPGKernsRDSystematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addictionAnn Intern Med200714611612717227935
- HartrickCTMultimodal postoperative pain managementAm J Health Syst Pharm200461Suppl 1S4S1015119755
- ShakibSProblems of polypharmacyAust Fam Physician20023112512811917821
- PasternakGWMolecular insights into mu opioid pharmacology: from the clinic to the benchClin J Pain201026Suppl 10S3S920026962
- NivDNemirovskyARudickVGellerEUrcaGAntinociception induced by simultaneous intrathecal and intraperitoneal administration of low doses of morphineAnesth Analg1995808868897726429
- BallantyneJCMaoJMOpioid therapy for chronic painN Engl J Med20033491943195314614170
- JooDTMechanisms of opioid tolerance: emerging evidence and therapeutic implicationsCan J Anaesth20075496997618056205
- SchröderWDe VryJTzschentkeTMJahnelUChristophTDifferential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic painEur J Pain20101481482120541444
- RahmanWD’MelloRDickensonAHPeripheral nerve injury-induced changes in spinal α2-adrenoceptor-mediated modulation of mechanically evoked dorsal horn neuronal responsesJ Pain2008935035918226963
- GarridoMJValleMCampaneroMACalvoRTrocónizIFModeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-O-desmethyltramadol, and a monoamine reuptake inhibitor, (−)-O-desmethyltramadol, in ratsJ Pharmacol Exp Ther200029535235910992001
- OssipovMHSuarezLJSpauldingTCAntinociceptive interactions between alpha 2-adrenergic and opiate agonists at the spinal level in rodentsAnesth Analg1989681942002537587
- SullivanAFKalsoEAMcQuayHJDickensonAHEvidence for the involvement of the mu but not the delta opioid receptor subtype in the synergistic interaction between opioid and alpha 2 adrenergic antinociception in the rat spinal cordNeurosci Lett199213965681357605
- SchröderWTzschentkeTMTerlindenRSynergistic interaction between the two mechanisms of action of tapentadol in analgesiaJ Pharmacol Exp Ther201133731232021262850
- TzschentkeTMChristophTKögelB(–)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic propertiesJ Pharmacol Exp Ther200732326527617656655
- TzschentkeTMDe VryJTerlindenRTapentadol hydrochlorideDrugs Fut20063110531061
- KressH(Editorial) Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally acting analgesics on the horizon?Eur J Pain20101478178320659810
- BuynakRShapiroDYOkamotoAEfficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III studyExpert Opin Pharmacother2010111787180420578811
- EtropolskiMSShapiroDYOkamotoARauschkolbCHäeusslerJSafety and tolerability of tapentadol extended release in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal phase 3 studyDiabetes200958A226A227 Abstract 852-P.
- WildJEGrondSKuperwasserBLong-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis painPain Pract20101041642720602712
- WeberHLangeRKuperwasserBTolerability of tapentadol prolonged release based on discontinuations due to adverse events in a 1-Year Randomized Phase 3 Safety StudyPoster presented at the 6th Triennial Congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC)Lisbon, Portugal9– 12 September, 2009
- LangeBKuperwasserBOkamotoAEfficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back painAdv Ther20102738139920556560
- HartrickCTapentadol immediate release for the relief of moderate-to-severe acute painExpert Opin Pharmacother2009102687269619795998